# Cisplatin-monotherapy in the Treatment of BRCA1 Positive Breast Cancer Patients in Poland

> **NCT01630226** · PHASE2 · UNKNOWN · sponsor: **Pomeranian Medical University Szczecin** · enrollment: 100 (estimated)

## Conditions studied

- BRCA1 Mutation
- Breast Cancer Invasive Nos

## Interventions

- **DRUG:** Neoadjuvant Cisplatin Chemotherapy

## Key facts

- **NCT ID:** NCT01630226
- **Lead sponsor:** Pomeranian Medical University Szczecin
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-06
- **Primary completion:** 2013-12
- **Final completion:** —
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2012-07-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01630226

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01630226, "Cisplatin-monotherapy in the Treatment of BRCA1 Positive Breast Cancer Patients in Poland". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01630226. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*